However, successful modulation of the PI3K-PTEN-Akt-mTOR pathway for anticancer therapy has been demonstrated with the mTOR inhibitor rapamycin and its analogues temsirolimus (CCI-779, Torisel; Wyeth Pharmaceuticals), everolimus (RAD0991; Novartis) and deforolimus (AP23573; ARIAD and Merck) (reviewed in [90]) While clinical efficacy has been demonstrated in a range of tumour types, including Phase II studies in patients with advanced endometrial cancer, objective response rates have been modest. This evidence concerns the gene MTOR and endometrial cancer.